4 Weeks Treatment of Type II Diabetic Patients With BI 44847
The primary objective of the current study is to investigate the safety and tolerability of BI 44847 in male and female patients with type 2 diabetes following oral administration of repeated doses of 100 mg b.i.d, 400 mg b.i.d. and 800 mg b.i.d. over 28 days.
A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 44847 after multiple dosing, including assessment of steady state.
Diabetes Mellitus, Type 2
Drug: BI 44847
Drug: placebo for BI 44847
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Selected Oral Doses of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes.|
|1224.4.49002 Boehringer Ingelheim Investigational Site|
|1224.4.49003 Boehringer Ingelheim Investigational Site|
|1224.4.49001 Boehringer Ingelheim Investigational Site|
|1224.4.31001 Boehringer Ingelheim Investigational Site|
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|